Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

VA Cooperative Studies Program (CSP)

Menu
Menu
Quick Links
Veterans Crisis Line Badge
My healthevet badge
 

CSP #576: VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)

 

Investigator Access

What's Available

 




Check with the study contact and publications for information on a public dataset, data archive, data enclave, or website where data might be available.

Available Documentation

Dates Data are Available

Access Criteria

Study Characteristics

Objectives

To determine the relative effectiveness and safety of 3 common alternate treatments for major depressive disorder.

Era of Service

All

Population

Patients within the VA health care system (85.2% men) diagnosed with major depressive disorder.

Study Design

Multisite randomized, single-blind, parallel-assignment clinical trial

Intervention
  • Switch to a different antidepressant, bupropion (switch group)
  • Augment current treatment with bupropion (augment-bupropion group)
  • Augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group)

Time Period

December 2012 – May 2015

Setting

National

N

1,522 participants

Response Rate

7,234 VHA patients were screened, 1,861 (25.7%) patients consented to participate and, of these, 1,522 (81.8%) were randomized.

Recruitment Method
  • Patients who were diagnosed with nonpsychotic major depressive disorder
  • Unresponsive to at least 1 antidepressant course
  • Met minimal standards for treatment dose and duration were recruited from 35 VA medical centers

Compensation

Unconfirmed

Data Collected

Primary outcome

  • Remission of symptoms of major depression during the acute treatment phase 

Secondary outcomes

  • Relapse in symptoms of major depression
  • Response measured as reduction in symptom score for major depression
  • Clinical assessment of a participant's level of depression and treatment response assessed by the Clinical Global Impression - Improvement (CGI -I) Scale

Additional outcomes

  • Suicidal ideation and behaviors
  • Anxiety
  • Quality of life
  • Health-related costs and cost-effectiveness
  • Medication adherence and satisfaction

Data Collection Methods
  • Physician and participant interview and self-report questionnaires
  • Vital sign and laboratory reports
  • Medical record review

Funding Sources
  • VA Cooperative Studies Program (CSP)
  • Bristol-Myers Squibb

Investigators

Principal Investigator: Somaia Mohamed, PhD
Study Chairs: Somaia Mohamed, PhD and Sidney Zisook, MD

Contact

Elizabeth Jobes, Elizabeth.Jobes@va.gov

Selected Publications

Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report. J Affect Disord. 2016 Dec;206:232-240.


Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S; and the VAST-D Investigators, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB 3rd, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11;318(2):132-145.

Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Res. 2015 Oct 30;229(3):760-70.

More Information

Study ClinicalTrials.gov site
ClinicalTrials.gov Identifier: NCT01421342
return to top go